RA Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

RA Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-6,196,143	Closed	-$110M	–	30
2018 Q3	$110M	Buy	6,196,143 +546,259	+10%	+$9.38M	5.88%	4
2018 Q2	$78M	Buy	5,649,884 +1,768,091	+46%	+$21M	5.06%	4
2018 Q1	$35.3M	Buy	3,881,793 +517,145	+15%	+$2.85M	2.7%	10
2017 Q4	$14.4M	Buy	+3,364,648	New	+$16M	1.21%	16

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

RA Capital Management's ECYT Position: Q4 2018 in Review

RA Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 6,196,143 shares — an estimated $110M sold.

RA Capital Management first reported a position in ECYT in Q4 2017 and held it in 4 quarters. The position peaked at $110M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

RA Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
RA Capital Management sold 6,196,143 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $110M.
RA Capital Management first reported a position in Endocyte, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
RA Capital Management's Endocyte, Inc. Common Stock position peaked at $110M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on RA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.